Research Paper Volume 12, Issue 2 pp 1685—1703

Figure 7. IL-33 promotes glioma tumorigenesis, EMT and stemness in vivo. (A) Glioma cells (Ln229) were subcutaneously injected into nude BALB/c mice in the presence or absence of 1ug/ml IL-33 and allowed to grow until tumors formed (4 weeks). (B and C) The tumor volume and tumor weight were monitored at 4 weeks after injection. Results are expressed as the mean of tumor volume ± SD; n=5; ****, P<0.0001. (D and E) primary glioma sections form mouse models were stained with proliferative maker Ki67, EMT related antibodies (E-cadherin, N-cadherin and Vimentin) and core stem genes (CD133 and Oct4) for IHC assay. (F) Glioma cells were subcutaneously transplanted into back flanks of NSG mice. After transplanted for 3 weeks, PBS, Anti-ST2, TMZ and Anti-ST2+TMZ were administered intraperitoneally (i.p.) into mice for consecutive 7 days. All NSG mice were killed in the sixth week. (G and H) tumor volume and weight were monitored and analyzed. Results are expressed as the mean of tumor volume ± SD; n=5; *, P < 0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.